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Abstract
In an abnormal fibrinogen (fibrinogen Naples) associated with
congenital thrombophilia we have identified a single base sub-
stitution (G - A) in the B,8 chain gene that results in an amino
acid substitution of alanine by threonine at position 68 in the
BB chain of fibrinogen. The propositus and two siblings were
found to be homozygous for the mutation, whereas the parents
and another sibling were found to be heterozygous. Individuals
homozygous for the defect had a severe history of both arterial
and venous thrombosis; heterozygous individuals had no clini-
cal symptoms. The three homozygotes had a prolonged throm-
bin clotting time in plasma, whereas the heterozygotes had a
normal thrombin clotting time. Fibrinopeptide A and B (FpA
and FpB) release from purified fibrinogen by human a-throm-
bin was delayed in both the homozygous propositus and a het-
erozygous family member. Release ofFpA from the normal and
abnormal amino-terminal disulfide knot (NDSK) corresponded
to that found with the intact fibrinogens, indicating a decreased
interaction of thrombin with the NDSK part of fibrinogen Na-
ples. Binding studies showed that fibrin from homozygous ab-
normal fibrinogen bound < 10% of active site inhibited a-
thrombin as compared with normal fibrin, while fibrin formed
from heterozygous abnormal fibrinogen bound - 50% of a-
thrombin. These results suggest that the mutation of BB Ala
68 -- Thr affects the binding of a-thrombin to fibrin, and that
defective binding results in a decreased release ofFpA and FpB
in both homozygous and heterozygous abnormal fibrinogens.
(J. Clin. Invest. 1992. 90:238-244.) Key words: amino-termi-
nal disulfide knot * dysfibrinogenemia * fibrinopeptide release.
polymerase chain reaction * a-thrombin binding
Introduction
The fibrinogen molecule is involved in the final phase ofblood
coagulation and consists ofpairs ofAa, Bf, and y chains linked
by 29 disulphide bonds (1). The conversion of fibrinogen to
fibrin is initiated by thrombin catalyzed cleavage offibrinopep-
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tides A and B (FpA and FpB)' from the amino terminus ofthe
Aa. and B,3 chains, respectively. The interaction of thrombin
with fibrin(ogen) involves multiple sites on both thrombin and
fibrin(ogen). An important domain of fibrinogen that interacts
with the catalytic'site of thrombin is located in the Aa chain
between amino acids 1 and 23 (2-6). The interaction ofthrom-
bin with fibrin through a site independent of the catalytic site
(anion-binding exosite) (7-12) is located in a cyanogen bro-
mide (CNBr)-derived fragment of the amino-terminal part of
the fibrin(ogen) molecule amino-terminal disulfide knot
(NDSK) (13-15). Binding of a-thrombin to fibrin by the an-
ion-binding exosite results in the removal of thrombin from
solution (7, 9). It has been proposed that this interaction plays
an important role in the regulation of thrombus formation in
vivo by limiting the amount of free active thrombin in the
circulation (7). Congenitally abnormal fibrinogens are valuable
tools for structure-function studies ofhuman fibrinogen. They
also provide a basis for correlating the molecular defect with
the clinical symptoms of affected individuals. Many abnormal
fibrinogens have been described (16), ofwhich a large number
show defective release of fibrinopeptides due to a mutation at
or near the thrombin cleaved bond (17-20). The structural
defect ofan abnormal fibrinogen (fibrinogen New York I) with
impaired thrombin binding to fibrin (21) has been determined.
This fibrinogen lacks amino, acids 9-72 in the Bfl-chain (22).
The patient, who was shown to be heterozygous, suffered from
thrombotic episodes (23). Fibrinogen Naples (Milano II) (24,
25) is another abnormal fibrinogen associated with congenital
thrombophilia. Preliminary work on fibrinogen Naples demon-
strated a defective interaction between bovine thrombin and
fibrin of the propositus (24). In this article we report the struc-
tural defect offibrinogen Naples, inferred from genetic analysis
of patient DNA using the polymerase chain reaction (PCR)
(26). The presence of the mutation in the family members, the
binding of human a-thrombin to fibrin, and the relationship
between the defect and clinical symptoms were also deter-
mined.
Methods
Patients. The propositus (11.3) developed postoperative deep-vein
thrombosis at the age of 33 yr. His sister (11. 1) had a stroke at the age of
25 yr due to thrombotic occlusion ofthe internal carotid artery and his
brother (11.2) had a stroke and thrombosis ofthe abdominal aorta at the
age of 21 yr. Another brother (11.4) of the propositus is asymptomatic,
as are his parents (. 1 and 1.2) (who are first cousins).
1. Abbreviations used in this paper: CNBr, cyanogen bromide; DFP,
difluorophosphate; FpA and FpB, fibrinopeptides A and B; NDSK,
amino-terminal disulfide knot; PCR, polymerase chain reaction; t-PA,
tissue-type plasminogen activator.
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Coagulation studies on plasma. Blood was collected by venipunc-
ture and anticoagulated with 0.1 vol of 0.11 M trisodium citrate.
Plasma was prepared by centrifugation at 2,300 g for 30 min at 4°C.
Thrombin clotting times were performed at 37°C with 200 Al ofplasma
and 50 Ml of human a-thrombin (1,000 National Institutes of Health
(NIH) U/mg; Protogen, Lafelfingen, Switzerland), dissolved in 0.15 M
NaCl containing 0.025% (wt/vol) gelatin to a concentration of25 NIH
U/ml. Reptilase (Boehringer Mannheim, Mannheim, FRG) clotting
time was performed as described (24). Fibrinogen concentration was
determined functionally according to Clauss (27) and immunologically
according to Mancini et al. (28).
Purification offibrinogen andNDSK Fibrinogen was purified from
plasma as described (29) and dialyzed against PBS for 24 h at 4°C.
NDSK was purified after CNBr digestion of purified fibrinogen (30) by
a fast protein liquid chromatography (FPLC) system equipped with a
Superose 12 column (Pharmacia, Uppsala, Sweden). The column was
equilibrated with 10% acetic acid containing 0.1 M NaCl and run at a
flow rate of 1.0 ml/min. The CNBr digest, 6 mg of protein in 0.3 ml,
was injected and 0.5-ml fractions were collected. Fractions 12-15 (Fig.
1) were pooled and analyzed on SDS-PAGE (3 1). The purified fibrino-
gen NDSK showed an Mr - 65,000 and a purity of - 90% (Fig. 1).
Pooled fractions were dialyzed against distilled water, lyophilized, and
dissolved in PBS to a concentration of 0.7 mg/ml. The fibrinogen and
NDSK concentrations were measured spectrophotometrically at 280
nm (fibrinogen, A'%"," = 15.0 (32), NDSK, A"%,"mn = 12.0 [calculated
from amino acid composition]); the yield of this purification was
- 65%.
Release offlbrinopeptides fromflbrinogen and NDSK. The rate of
FpA and FpB release was determined at 37°C with 100 Ml offibrinogen
solution (4.0 mg/ml) orNDSK solution (0.7 mg/ml) and 10 M ofeither
I NIH U/ml human a-thrombin or 1:30 diluted Reptilase. The reac-
tions were stopped at various times by placing the samples in a boiling
water bath for 2 min. The samples were centrifuged at 12,000 g for 10
min, and 50 Ml of the supernatant was analyzed by HPLC (LKB Pro-
dukter, Bromma, Sweden) on a C- 18 reversed-phase column (Chrom-
pack, Middelburg, The Netherlands) (24, 33). The amount ofFpA and
FpB released was determined by measuring the peak area.
Fibrin polymerization. Purified fibrinogen was dissolved in PBS to
a concentration of 2.0 mg/ml. 1 ml of this solution was clotted by
adding 0.1 ml ofhuman a-thrombin (25 NIH U/ml) or undiluted Rep-
tilase over a period of 5 h at 37°C. The fibrin was collected by centrifu-
gation, washed four times with PBS, and subsequently dissolved in 20






fibrin monomers was obtained by increasing the pH and performed by
adding 60 ,d of the fibrin monomer solution to 740 ,1 of 0.1 M Tris/
HCI, pH 7.5. The increase in absorbance at 350 nm was recorded as a
function oftime on a spectrophotometer (SP 1700; Pye Unicam, Cam-
bridge, UK).
Preparation of ["C]difluorophosphate (DFP) a-thrombin. 1 ml of
human a-thrombin, dissolved at 1 mg/ml in 10mM Tris/HCl, pH 8.3,
containing 0.75 M NaCl, was incubated with 100 ,d of ['4C]DFP (108
mCi/mmol, 1.9 MM/ml; New England Nuclear, s'Hertogenbosch, The
Netherlands) for 90 min at 250C. Subsequently 10 Ml of a 0.1 M DFP
solution in dry isopropanol was added, and incubated for 30 min. The
sample was dialyzed against 50 mM Tris/HCl, pH 7.5, 100 mM NaCl
for 24 h at 40C. Protein concentration was measured spectrophotomet-
rically at 280 nm (A'%"C"' = 18.0 [34]). The amidolytic activity ofinhib-
ited thrombin, determined by using the synthetic substrate S-2238
(KabiVitrum, Stockholm, Sweden) according to the manufacturer's
instructions, was < 0.05% of the original activity. The relative a-, ,B-,
and y-thrombin content was determined by SDS-PAGE (31) followed
by autoradiography. The amount of a-thrombin was > 95% (Fig. 2).
To prevent nonspecific adsorption, gelatin (final concentration 0.1%
wt/vol) was added to the thrombin solution, and this solution was
stored at -70°C.
['"C]DFP a-thrombin binding to fibrin. Fibrinogen was dialyzed
against 50 mM Tris/HCI, pH 7.5, 100 mM NaCl, and diluted to 0.5
mg/ml. Part of this fibrinogen solution was radiolabeled with 125I
(Amersham, Buckinghamshire, UK) as described (35). To 0.15 ml of
fibrinogen, 50 ul ofsolutions containing different amounts of['4C]DFP
inhibited a-thrombin diluted in 50 mM Tris/HCI, pH 7.5, 100 mM
NaCI, 0.1% (wt/vol) gelatin were added. Subsequently, fibrin forma-
tion was induced by incubating with 10 ,l ofundiluted Reptilase solu-
tion for 30 min. Fibrin was collected by centrifugation for 10 min at
12,000 g. The pellet was washed three times with 0.5 ml 50 mM Tris/
HCI, pH 7.5, 100 mM NaCl, and dissolved in 0.2 ml of 50 mM acetic
acid. The sample was mixed with 3.0 ml of scintillation fluid (Ultima
Gold, Packard Instrument Co., Inc., Downers Grove, IL) and 14C was
counted (Tricarb 1900 CA, Packard Instrument Co., Inc.). The
amount of fibrin formed was determined in parallel experiments con-
taining trace amounts of '25I-fibrinogen. After dissolving the fibrin in
acetic acid, the amount of radioactivity was counted in a y counter
(Cobra, Packard Instrument Co., Inc.). Under these conditions normal
fibrinogen and fibrinogen Naples II.3 and II.4 were 93-96% clottable.
Fibrin stimulation oftissue-type plasminogen activator (t-PA). The
stimulatory capacity of Reptilase and thrombin-induced fibrin mono-
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- 14.4 Figure 2. Autoradiogram of ['4C]DFP a-throm-
bin after SDS-PAGE under reducing conditions.
mers, prepared as described for fibrin polymerization, was assayed as
described previously (36).
PCR. Genomic DNA was isolated from blood cells as described
(37). Oligonucleotides were synthesized on a model 380A DNA synthe-
sizer (Applied Biosystems, Inc., Foster City, CA). Oligonucleotides
ala(5'GCAGATAGTGGTGAAGGTGAC3') and a lb(5'GTTATTG-
GCTGAGGAAAAATCGCC3') were used to amplify the part of the
a-chain gene, coding for amino acids 1-95. Oligonucleotides
#l a(5'GGTGTTGGAATAGTTACATTCC3') and fl b(5'GGTGTG-
TGAGTTCTTCTGGA3') were used to amplify the part of the Bfl-
chain gene, coding for amino acids 9-209. fl2a(5'GCCTCTAAGGTT-
GTAGGAATTCTTCAG3')andfl2b(5'ATCAGTGCACCCACCAAG-
TCTGGG3') were used to amplify the ,B-gene segment coding for
amino acids 9-72. Oligonucleotidesy Ila(5'GCTCTTCACAAAACG-
TTGTTTAAAATGGAATTCTGG3')andy lb(5'CAGTCTTGCAGA-
GCAAATTAAAACAAAAATCCTTAC3') were used to amplify the
part of the y-chain gene coding for amino acids 1-108. Amplification
by PCR (26) was performed in a 1O0-,l reaction volume containing 1
gg of genomic DNA, 0.2 mM of each dNTP (Pharmacia), 0.2 ,uM of
each primer in lx reaction buffer (10 mM Tris/HCl, pH 8.3 at 25°C,
50 mM KCI, 3.0 mM MgCl2 and 0.001% (wt/vol) gelatin). The DNA
was denatured at 95°C for 8 min and 2.0 U Taq DNA polymerase
(Perkin-Elmer Cetus, Emeryville, CA) were added. Cycles consisted of
a 1-min 95°C, 0.5-min 60°C, and 3-min 70°C incubation. After 30
cycles 5 gul of the sample was analyzed on a 1.0% agarose gel (A-601 3,
Sigma Chemical Co., St. Louis, MO).
Direct sequencing PCR fragments. PCR samples were run on a 1%
(wt/vol) ultralow gelling agarose gel (A-5030, Sigma Chemical Co.).
The band with the appropriate size, as predicted by the genomic se-
quence ofthe Aa (16), Bf (16, 38), andy chain genes (36), was cut out
of the gel and heated to 65°C. 1 gil of the melted agarose, containing
- 10 ng of DNA, was mixed with 1 gl of the appropriate PCR primer
(60 ng), and 2 ,ul of SX sequence buffer (T7 sequence kit, Promega
Corp., Madison, WI), the volume was brought up to 10 gl with distilled
water. The mixture was heated to 95°C for 3 min and immediately put
on ice. Labeling and termination reactions were performed using the
T7 DNA sequence kit (Promega Corp.) according to the manufac-
turer's instruction.
Southern blot analysis offamily members and normal population.
Amplified fragments of the BB chain gene containing the sequence
coding for amino acids 9-72 (- 50 ng) were run on a 2% (wt/vol)
agarose gel (A-6013, Sigma Chemical Co.). The gel was washed (twice
for 15 min) with 0.5 M NaOH, 1.5 M NaCl, and the denatured DNA
was transferred to a nylon membrane (Hybond N, Amersham) using
the Vacugene blotting system (LKB Produkter). 100 ng of sequence-
specific oligonucleotides (f-normal: 5TGTCTTCACGCTGACC-
CAG3 and f-Naples: 5TGTCTTCACACTGACCCAG3') were radio-
labeled with T4 polynucleotide kinase (Gibco BRL, Breda, The Neth-
erlands) according to the manufacturer's instructions, using
[y-32P]ATP (3,000 Ci/mmol, Amersham). The blots were washed with
2x SSC (Ix SSC contains 0.15 M NaCl and 0.015 M Na3C6H507) and
hybridized with the labeled oligonucleotides in 40 ml of 7% SDS, 0.36
M Na2HPO4, 0.14 M NaH2PO4, and 10 mM EDTA for 4 h at 42°C.
Blots were washed three times for 30 min at 58°C with 6x SSC contain-
ing 0.5% (wt/vol) SDS, and exposed to x-ray film (X-AR, Eastman
Kodak Co., Rochester, NY) for 16 h.
Results
Coagulation studies on plasma. Table I shows the results ofthe
thrombin and Reptilase clotting time assays and of the immu-
nological and functional fibrinogen assays performed on
plasma of normal individuals, the propositus (II.3), and his
family members. The propositus and two of his siblings (I. 1,
11.2) showed a strongly delayed thrombin clotting time, but a
normal Reptilase time. They also showed a discrepancy be-
tween the immunologically and the functionally determined
fibrinogen concentration. Three other family members (father,
mother, and one other sibling: 1. 1, 1.2, and 11.4) showed normal
thrombin and Reptilase clotting times and no significant differ-
ence between the immunologically and functionally deter-
mined fibrinogen concentration.
Fibrinopeptide release from fibrinogen. Fig. 3 shows the
thrombin-catalyzed release of the FpA and FpB from normal
fibrinogen, fibrinogen Naples 11.3 (propositus with prolonged
thrombin clotting time), and Naples II.4 (sibling with normal
thrombin clotting time). FpA release (Fig. 3 A) from both fi-
brinogens Naples 11.3 and 11.4 is strongly delayed as compared
with normal fibrinogen. There is a large difference in the
amount of FpA released after 60 min from normal fibrinogen
(100%) and from fibrinogens Naples 11.4 (63%) and Naples 11.3
(24%). Fibrinogen Naples I.3 also showed a lag of - 10 min
before any FpA could be detected; fibrinogen Naples II.4 and
normal fibrinogen did not show this lag period. The release of
FpB (Fig. 3 B) from fibrinogens Naples 11.3 and II.4 was also
strongly delayed as compared with normal fibrinogen. After 60
min, normal fibrinogen released 92% of FpB, fibrinogen Na-
ples 11.4 released 30% of FpB, and Naples 11.3 only released
10% of FpB. With normal fibrinogen and fibrinogen Naples
II.4, FpB was detected after a lag period of 2.5 min; with fibrin-
ogen Naples I.3 this lag period was 25 min. Reptilase-cata-
lyzed release ofFpA was the same for all three fibrinogens (data
not shown).
Fibrinopeptide release ofNDSK. Fig. 4 shows the release of
FpA and FpB by thrombin from NDSK purified from normal
fibrinogen and fibrinogen Naples 11.3. As was found with intact
fibrinogens, the release of FpA from NDSK Naples 11.3 was
strongly delayed as compared with that of normal NDSK. The
release of FpA from both normal and Naples I.3 NDSK was
Table I. Plasma Coagulation Studies
Plasma clotting time Plasma fibrinogen
Human











































_- 0 _.._._0 Figure 3. Release of fibrinopeptides
60 0 20 40 60 from intact fibrinogen by human
a-thrombin, determined by HPLC.
(A) FpA and (B) FpB release from
(a) normal fibrinogen (A) fibrinogen
Naples 11.4, and (v) fibrinogen Na-
TIME (min) ples 11.3.
identical to the release from intact normal and Naples 11.3 fi-
brinogen, respectively (compare Fig. 4 with Fig. 3 A).
The release ofFpB from NDSK Naples I.3 was delayed as
compared with normal NDSK. In contrast to the FpA release,
the FpB release from normal NDSK is slower than the FpB
release from intact normal fibrinogen (compare Fig. 4 with Fig.
3 B). However, the FpB release of NDSK Naples II.3 was ap-
proximately the same as the FpB release of intact fibrinogen
Naples II.3 (compare Fig. 4 with Fig. 3 B).
The release of FpA by Reptilase from NDSK Naples II.3
was the same as that from normal NDSK (data not shown).
Fibrin polymerization. The polymerization profiles of fi-
brin monomers obtained from fibrinogen Naples I.3, by Rep-
tilase and thrombin, were similar to the profiles obtained with
the corresponding monomers prepared from normal fibrino-
gen (data not shown). These results are consistent with the
normal Reptilase clotting time and prothrombin-staphyloco-







Figure 4. Release of fi-
brinopeptides from pu-
rified NDSK by human
a-thrombin determined
by HPLC. (e)FpA and
o l Fe~ (o) FpB form normal
0 20 40 60 NDSK, and (.) FpA and
(o) FpB from NDSK
TIME (min) Naples 11.3.
ported previously (24), and indicate that the mutation in fibrin-
ogen Naples does not affect the fibrin polymerization.
Binding ofactive-site inhibited human a-thrombin tofibrin.
Fig. 5 shows that the binding of[14C]DFP inhibited a-thrombin
to Reptilase-induced fibrin clots from normal fibrinogen and
fibrinogens Naples II.3 and II.4. With normal fibrin, thrombin
binding increased with increasing thrombin concentration,
reaching saturation at - 1 mol of inhibited a-thrombin per
mol of fibrin. With fibrin Naples 11.4, the shape of the binding
curve was similar, but saturation was achieved at - 0.5 mol of
thrombin per mol of fibrin. Thrombin bound poorly to fibrin
Naples I.3 with < 0.1 mol ofthrombin bound/mol of fibrin at
the highest thrombin concentration tested. Scatchard analysis
of the binding data for normal fibrinogen and Naples II.4 (in-
set, Fig. 5) indicated one class of binding sites. The maximal
molar binding ratio (thrombin/fibrin) for normal fibrin was
1.1±0.25 with Ka = 12.7±3.0 X I05 M-', for fibrin Naples 11.4
this ratio was 0.70±0.15 with Ka = 13.8±3.1 x 105 M-'. No
Scatchard plot could be constructed for the binding data ob-
tained with fibrin Naples II.3, because of low binding under
these conditions.
Fibrin stimulation oft-PA-inducedplasminogen activation.
The stimulatory effect of fibrin Naples 11.3 on t-PA-induced
plasminogen activation was normal, as compared with fibrin
prepared from normal fibrinogen, by both Reptilase and
thrombin (data not shown). These results indicate that the in-
teraction among fibrin Naples, t-PA, and plasminogen in a
purified system is not affected by the mutation in fibrinogen
Naples. This concurs with the previously described normal in-
teraction between fibrin Naples and several components of the
fibrinolytic system in plasma (24). It also indicates that the
observed thrombophilia in the affected individuals is not re-
lated to defective fibrinolysis.
Amplification and direct sequencing ofgenomic DNA frag-
ments. Based on the evidence of fibrinopeptide release by
thrombin, which showed that the defect was located in the
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Figure 5. Binding of [14CJDFP a-thrombin to Reptilase-induced fibrin
clots. (.) Normal fibrinogens; (v) fibrinogen Naples 11.4; and (v) fi-
brinogen Naples 11.3. Inset: Scatchard plot of binding data (normal
fibrinogen and fibrinogen Naples 11.4).
NDSK part of fibrinogen Naples, we amplified the genomic
DNA which codes for NDSK, specifically amino acids Aa
1-51, B/3 1-1 18, and y 1-79 of the fibrinogen molecule. After
amplification, fragments with the sizes predicted from the geno-
mic DNA sequences for the human fibrinogen Aa, B/3, and y
chain genes (16, 38, 39) were sequenced. The fragments con-
taining the Aa or My gene sequence were completely normal,
whereas the B/3 fragment ofNaples I.3 had a single base substi-
tution (Fig. 6) in the codon normally coding for alanine at
position 68. This mutation changed the codon GCT (alanine)
to ACT which codes for threonine. The normal sequence was
completely missing in Naples II.3, indicating that the proposi-
tus was homozygous for this mutation.
Detection ofmutation infamily members and normal indi-
viduals. The amplified B/3 fragments of the family members
were hybridized with two synthetic oligonucleotides, one with
the normal sequence (/3-normal) and the other with the se-
quence found in fibrinogen Naples (,3-Naples). Fig. 7 shows










Figure 6. DNA sequence of BP3-chain gene fragment after amplifica-
tion coding for amino acids 9-209 (arrows indicate the mutation).
-1C= <2 Figure 7. (Top) Pedigree
ofthe family. The pro-
____ positus (11.3) has symp-
toms ofvenous throm-
1 4b 1 * 2 3 4 boembolism, and his
sister (11. 1) and brother
(11.2) have symptoms
A_ of arterial thrombosis,
A _ =_ * whereas the parents 1.1
and 1.2 (first cousins)
Ii 12 11it 112 113 114 nor and the brother 11.4 are
asymptomatic. (Bottom)Southern blot analysis
of the Bft chain gene
fragment of normal and
Naples family using se-
-J quence-specific oligonucleotides. (A) Normal sequence; (B) Naples
4 sequence.
hybridize with both oligonucleotides, indicating that the asymp-
tomatic family members are heterozygous for the mutation
found in the B/3 fragment. Amplified B/3 fragments of Naples
I. 1, 11.2, and 11.3 hybridized only with the ,8-Naples oligonucle-
otide, showing that the symptomatic family members were ho-
mozygous for the mutation. The corresponding fragment of
120 normal individuals hybridized only with the /3-normal oli-
gonucleotide (data not shown), indicating that the mutation
was not a common polymorphism.
Discussion
The mutation in fibrinogen Naples is associated with a defec-
tive release ofFpA and FpB by thrombin. Because this defect
was present in the purified NDSK fragment of fibrinogen Na-
ples, we amplified and sequenced the genomic DNA segments
encoding the NDSK fragments Aa, B/3, and y chains. Sequence
analysis of the amplified products demonstrated that the pro-
positus (11.3) was homozygous for a single base substitution in
the codon for B/3 Ala 68 (GCT) resulting in a Thr (ACT) at this
position. Southern blot analysis using sequence specific oligo-
nucleotides showed that all three asymptomatic family
members were heterozygous for the mutation while the three
symptomatic members (including the propositus) were homo-
zygous. This indicates that the homozygous mutation (B/3 68
Ala--oThr) is associated with thrombophilia, and that this type
of dysfibrinogenemia is clinically recessive.
By using fibrinogen purified from the homozygous proposi-
tus, a-thrombin-catalyzed FpA release was delayed relative to
normal fibrinogen. The rate of FpA release from fibrinogen
isolated from a heterozygous family member (II.4) was approxi-
mately half that of normal, indicating that heterozygous indi-
viduals have both normal and abnormal molecules. Human
a-thrombin-catalyzed release ofFpA from the purified NDSK
fragment of normal fibrinogen was identical to that of intact
fibrinogen. As previously reported (2, 3), this provides evidence
that the NDSK fragment contains all the essential information
for an effective interaction ofthrombin with fibrinogen. Analo-
gously, NDSK from the homozygous fibrinogen Naples I.3
had the same decreased rate of FpA release by a-thrombin as
intact fibrinogen Naples 11.3, indicating that the defective do-
main is located in the NDSK part of the fibrinogen Naples
molecule. The release of FpA by Reptilase from fibrinogen
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Naples and NDSK Naples 11.3 was normal, indicating that the
mutation did not affect the substrate cleavage site ofFpA in the
Aa-chain.
The rate of FpB release from homozygous fibrinogen Na-
ples 11.3 was also strongly delayed as compared to normal fi-
brinogen. The FpB release from NDSK Naples 11.3 was approx-
imately the same as from intact fibrinogen Naples 11.3, which is
in contrast with the slower release ofFpB from normal NDSK
as compared with normal fibrinogen. The reduced release of
FpB from normal NDSK as compared with normal intact fi-
brinogen, can be explained by the accelerating effect of fibrin
polymerization on FpB release (40-43), which is absent when
using NDSK. The similar release of FpB from NDSK Naples
II.3 and intact fibrinogen Naples 11.3 suggests that this accelerat-
ing effect of fibrin polymerization is absent in fibrin Naples.
Active site-inhibited thrombin binds to fibrin by a site inde-
pendent of the catalytic site designated the anion-binding exo-
site (7-12). Active site-inhibited human a-thrombin bound to
normal fibrin formed by Reptilase. In contrast, thrombin bind-
ing to fibrin Naples 11.3 was very low whereas thrombin bind-
ing to fibrin Naples II.4 was about half that of normal fibrin.
Scatchard analysis ofthe binding data indicated a single class of
binding sites with maximal binding of 1.1 mol ofthrombin per
mole of fibrin and Ka = 1.3 X 106 M-'. This approximates the
strongest binding (Ka = 5.8 X IO' M-') determined by Liu et al.
(7), who reported that fibrin contains two classes of binding
sites. Our data determined under different experimental condi-
tions indicate only one class of binding sites. Irrespective of
these differences, many studies indicate that a-thrombin binds
to fibrin by a site distinct from its catalytic centre and that the
binding site on fibrin is located in the NDSK part ofthe fibrin-
ogen molecule (13-15). The results with fibrinogen Naples indi-
cate that the Bo Ala 68 Thr substitution fully disrupts
thrombin binding at this site.
The loss of the anion-binding exosite from a-thrombin in
the formation of f- and y-thrombins, results in a reduced clot-
ting activity of f- and y-thrombins for fibrinogen (9, 13). This
suggests that the reduced fibrinopeptide release observed in
fibrinogen Naples could be fully accounted for by the decreased
noncatalytic binding ofa-thrombin to fibrinogen Naples. How-
ever, the possibility of influence by amino acid substitution in
fibrinogen Naples on the catalytic binding of a-thrombin can-
not be ruled out.
Fibrinogen New York I (23) also showed a decreased re-
lease of FpA and FpB, and a defective binding of thrombin
(24). In contrast to fibrinogen Naples, the defect in fibrinogen
New York I is extensive, in that amino acids Bol 9-72 are de-
leted. This large deletion is likely to have multiple effects on the
defective fibrinogen structure, particularly because Bo Cys 65,
which normally forms a disulphide bond with Aa Cys 36, is
missing. Without information about the three-dimensional
structure of NDSK, it is difficult to determine the exact influ-
ence of the BJ3 68 Ala -> Thr substitution on the binding to
thrombin. One possible explanation is that Bo 68 alanine par-
ticipates in a nonpolar interaction with thrombin and that this
is disrupted by threonine. Alternatively, the slightly larger side
chain of threonine could lead to incorrect folding or disulfide
bond formation of this part of the fibrinogen molecule, pre-
venting thrombin binding.
It has been suggested that thrombin binding to fibrin is a
mechanism that prevents active thrombin from existing free in
the circulation (7). In the absence of this binding, free active
thrombin in the circulation results in excessive coagulation
and/or platelet aggregation which in its turn can lead to throm-
bosis. From the dramatic history of thrombophilia in the fam-
ily with fibrinogen Naples and the genetic analysis of the fam-
ily, it is clear that the occurrence of thrombosis is related to the
defect in fibrinogen Naples only in homozygous family
members. The mutation in fibrinogen Naples (Bo 68 Ala --
Thr) prevents thrombin binding to fibrin and is correlated with
thrombophilia. These results demonstrate that thrombin bind-
ing to fibrin is an important in vivo mechanism to limit the
presence of free active thrombin in circulation and to prevent
excessive coagulation and/or platelet activation leading to
thrombosis.
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